| Literature DB >> 24952856 |
Rury R Holman1, Mary A Bethel2, Juliana C N Chan3, Jean-Louis Chiasson4, Zoë Doran2, Junbo Ge5, Hertzel Gerstein6, Yong Huo7, John J McMurray8, Lars Ryden9, Winitha Liyanage2, Stefan Schröder10, Michal Tendera11, Michael J Theodorakis2, Jaakko Tuomilehto12, Wenying Yang13, Dayi Hu14, Changyu Pan15.
Abstract
Patients with cardiovascular disease and impaired glucose tolerance are at increased risk of cardiovascular events and type 2 diabetes mellitus (T2DM). Lifestyle modification or pharmacological intervention can delay progression to T2DM, but there is no clear evidence that they reduce cardiovascular risk in this population. Acarbose, an α-glucosidase inhibitor that lowers postprandial blood glucose, has been shown to reduce T2DM risk by 25%, and possibly cardiovascular risk in impaired glucose tolerance subjects without cardiovascular disease.Entities:
Mesh：
Substances：
Year: 2014 PMID： 24952856 DOI： 10.1016/j.ahj.2014.03.021
Source DB: PubMed Journal: Am Heart J ISSN： 0002-8703 Impact factor: 4.749